cas 4101-30-8|| where to buy 2'-Amino-4',5'-dimethoxyacetophenone

Nombre del producto:2'-Amino-4',5'-dimethoxyacetophenone

IUPAC Name:1-(2-amino-4,5-dimethoxyphenyl)ethan-1-one

Unidad de embalaje	Stock disponible	Precio($)
CM343560-25g	in stock	ǊǯǊ
CM343560-100g	in stock	źȎǊ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4101-30-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :4101-30-8; Fórmula molecular:C10H13NO3; Punto de fusión:-; Código de sonrisas:CC(C1=CC(OC)=C(OC)C=C1N)=O; Densidad:

: Número de catálogo:CM343560; Peso molecular:195.22; Punto de ebullición:; Nº Mdl:MFCD00016646; Almacenamiento:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Cabozantinib; On August 21, 2023, Exelixis and Ipsen announced that the global phase 3 CONTACT-02 study of cabozantinib (Cabometyx ®) in combination with atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) met the primary endpoint of progression-free survival (PFS) in an interim analysis.
Prostate cancer is the fourth most common cancer worldwide and the second most common cancer among men. At present, the drugs approved for the treatment of CRPC are basically AR inhibitors or PARP inhibitors, and the combination therapy of Cabozantinib + Atezolizumab is expected to become a new treatment option for such patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.